Neurology Today in 5 podcast

Advances in cell therapies for Parkinson’s, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs

0:00
4:14
Manda indietro di 15 secondi
Manda avanti di 15 secondi

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny. 

Altri episodi di "Neurology Today in 5"